OnKure Therapeutics, Inc. (OKUR)

The investment case for OnKure Therapeutics is currently defined by severe distress rather than opportunity. Fundamentally, the company is a deep-value trap; despite trading at less than 60 cents on the dollar relative to book value, the business has erased over 95% of its value over the last four years. The market has correctly priced a catastrophic failure in execution, evidenced by three consecutive years of negative annual returns ending with a massive 84% drop last year. While the balance sheet remains technically intact due to a recent capital raise, the relentless price erosion and negative cash flows signal that the core business model is failing to generate value. Short-term momentum is broken, with the stock trading well below its 50-day and 200-day averages, reflecting a persistent downtrend. The statistical forecast models also lean slightly negative, reinforcing the view that the immediate outlook is bleak. There is no dividend to provide income, and the lack of analyst coverage suggests the stock has been effectively abandoned by institutional capital. Until there is concrete evidence of a turnaround in clinical trials or revenue generation, the prudent assessment is to avoid this security entirely.